AMSTERDAM, May 16, 2016 /PRNewswire/ --
EuroPCR congress marks the first
year anniversary of the Philips Volcano
merger, delivering less invasive and more
precise personal care for interventional
cardiology
Royal Philips (NYSE: PHG, AEX: PHIA) today announced its
participation in the EuroPCR 2016 Congress in the field of
interventional cardiology, taking place in Paris, France, May 17 -
20, 2016. Philips booth presence in the exhibition (M71 on
level 2) will showcase the companies' ongoing commitment to
delivering advanced technology and integrated solutions that
further advance the field of coronary, peripheral and structural
heart diseases.
Philips will also participate in two scientific sessions and
host hands-on experiences and live demos in the Training Village to
help attending cardiologists experience and fully understand the
everyday clinical benefits of integrated solutions to help enhance
procedural outcomes. An interactive experience at the booth will
also bring to life a fully integrated cath lab through virtual
reality.
Cardiovascular disease is the leading global cause of death,
accounting for 17.3 million deaths per year, and is expected to
grow to more than 23.6 million by 2030.[1] Cardiology is
one of the top health technology priorities for Philips, which
provides integrated solutions helping clinicians treat
cardiovascular disease by speeding detection, diagnosis and
treatment, driving effective recovery and home care, and
encouraging prevention and healthy living.
"A continuous strong growth area in interventional
cardiovascular care is Image Guided Therapy. The broad portfolio of
Philips Volcano solutions has begun personalizing the future of
minimally invasive procedures for every patient," said Bert van Meurs, CEO Image Guided Therapy,
Philips. "We will be showcasing our market leading technologies at
EuroPCR, bringing to life our integrated solutions and strategies
for interventional cardiology to optimize outcomes while managing
costs."
Philips' leadership in image-guided interventional solutions
across X-ray systems, navigation software and Live 3D TEE
ultrasound imaging, combined with Philips Volcano's leadership in
intravascular therapy guidance tools - together enable effective
diagnosis and treatment.
Philips is expanding and accelerating growth with integrated
interventional suites that lead to procedure innovation with
technologies being showcased at EuroPCR including:
- AlluraClarity with ClarityIQ technology -
provides high quality images at a low X-ray dose for cardiac
interventions
- HeartNavigator - provides immersive user experience and
automated tasks simplify planning, measurement, device selection,
and choice of excellent X-ray viewing angle for TAVI, LAA, Mitral
and other SHD procedures
- EchoNavigator - fuses live 3D TEE and X-ray in real time
to provide live image guidance in the 3D space, supporting
physicians in complex structural heart procedures to decide, guide
and confirm the appropriate treatment path, enabling better patient
care and more cost effective care
- IntelliSpace Cardiovascular - streamlines patient
information management to analyze, access and manage cardiovascular
information from a single workspace - anytime.
- CORE FM and iFR Scout - reveals the physiological
profile of the entire vessel for better informed treatment
decisions when dealing with diffuse disease or serial lesions
- SyncVision Precision Guidance - helps reduce the risk of
geographic miss, which study data suggests may occur in 66.5% of
PCIs[2]
During EuroPCR, Philips will also host a number of on-site
events, including:
- Case in Point session "Strategies for complex PCI treatment:
optimizing your procedural outcomes while managing costs through
novel and innovative technologies" (Wednesday, May 18 from 16:30 - 18:00 CET, Room 241). The recording will
be made available afterwards after subscribing here
- Symposium co-hosted with Abbott Vascular discussing the
controversies in intervention and imaging (Wednesday, May 18 from 16:30 - 18:00 CET, Theatre Havane)
- Training Village with daily opportunities for hands-on
experience and live demonstrations of key Philips Volcano
technology, including an interactive cath lab, through virtual
reality
For more information on Philips' presence at EuroPCR 2016, visit
http://www.philips.co.uk/healthcare/about/events-calendar/europcr
and follow the #EuroPCR conversation @PhilipsLiveFrom.
This material is not meant for distribution in the USA.
About Royal
Philips
Royal Philips (NYSE: PHG, AEX:
PHIA) is a leading health technology company focused on improving
people's health and enabling better outcomes across the health
continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. The company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' wholly owned
subsidiary Philips Lighting is the global leader in lighting
products, systems and services. Headquartered in the Netherlands, Philips posted 2015 sales of
EUR 24.2 billion and employs
approximately 104,000 employees with sales and services in more
than 100 countries. News about Philips can be found at
http://www.philips.com/newscenter.
1. 2015 Heart Disease and Stroke Statistics Update, American
Heart Association, Centers for Disease Control and Prevention, the
National Institutes of Health, et al.
2. Costa et al. Impact of Stent Deployment Procedural Factors on
Long-term Effectiveness and Safety of Sirolimus-Eluting Stents
(Final results of the Multicenter Prospective STLLR Trial). Am J
Cardiol 2008 Jun 15; 101(12):1704-11.
For further information, please contact:
Fabienne van der Feer
Philips Image Guided Therapy
Tel: +31-6-22698001
Email: fabienne.van.der.feer@philips.com
Tom Osypian
Philips Volcano
Tel: +1-858 -720 4086
Email: tom.osypian@philips.com